CD19 and Burkitt lymphoma: It was demonstrated in an in vivo chronic lymphocytic leukemia (CLL) relapse model after CD19 CAR-T treatment, as well as in vitro experiments using primary CLL cells and CLL and Burkitt lymphoma cell lines co-cultured with CD19 CAR-T cells.